DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-445/S-023 and S-024

Wyeth Pharmaceuticals
Attention: Mary Ellen Menz, RN, MBA, JD
Manager, Worldwide Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Menz:

Please refer to your supplemental new drug applications dated September 10, 2003 (S-023), and October 30, 2003 (S-024), received September 11, 2003, and October 31, 2003, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for MINOCIN® (minocycline hydrochloride) Oral Suspension.

This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

These supplemental new drug applications provide for revisions to the label to comply with the Final Rule entitled "Labeling Requirements for Systemic Antimicrobial Drug Products Intended for Human Use" (68FR 6062, February 6, 2003) (S-023), and to incorporate safety information under the ADVERSE REACTIONS section of the package insert (S-024).

We completed our review of these applications, and they are approved, effective on the date of this letter.

The final printed labeling (FPL) must be identical to the labeling for the package insert submitted on September 10, 2003 (S-023) and October 30, 2003 (S-024).

Please submit the FPL electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – NDA." Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplements NDA 50-445/S-023 and S-024." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Regulatory Project Manager, at (301) 827-2207.

Sincerely,

{See appended electronic signature page}

Janice M.Soreth, MD
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth

5/27/04 04:23:31 PM